AREDS2 Eye Formula
One of the few supplement formulas with a large, government-funded RCT behind it — but only for a specific population: people who already have intermediate age-related macular degeneration, or advanced AMD in one eye. It slows progression modestly; it does not prevent AMD in healthy eyes or improve vision.
Where to buy
-
iHerb NuBest, Eye Health With AREDS2 Nutrients, 60 Vegetarian Capsules Ships to 180+ countries · welcome discount for new customersView on iHerb
Each store sells its own product: check brand, amount and price on the store page before buying. Prices change; the date shows when we last checked.
Referral link — this site may earn a commission on purchases.
What the science says
- Slows progression to advanced AMD in people with intermediate disease Strong evidence
The original AREDS trial showed that antioxidants plus zinc lowered the odds of advanced AMD, and AREDS2 kept that base while swapping beta carotene for lutein/zeaxanthin; in its 10-year follow-on, lutein/zeaxanthin gave a hazard ratio of 0.91 (95% CI 0.84-0.99) for late AMD, and 0.80 (0.68-0.92) among those who had been assigned beta carotene. The 2023 Cochrane review concludes that this supplementation probably slows progression to late AMD in people who already have the disease: about 78 fewer cases per 1,000 people with intermediate AMD, but only about 4 fewer per 1,000 with early AMD. It is not a cure.
- Who was studied
- AREDS enrolled 3,640 people aged 55-80 with drusen or advanced AMD in one eye (average 6.3 years); AREDS2 enrolled 4,203 people aged 50 to 85 with large drusen in both eyes or advanced AMD in one eye (median 5 years, 3,882 followed to 10 years); the Cochrane review covers 26 trials with 11,952 people.
- Result
- Progression to advanced (late) AMD and loss of at least 15 letters of vision; the AREDS formula reduced both.
- Effect size
- In AREDS, antioxidants plus zinc gave an odds ratio of 0.72 (99% CI 0.52-0.98) for advanced AMD and 0.73 (0.54-0.99) for moderate vision loss; the Cochrane pooled odds ratio is 0.72 (95% CI 0.58 to 0.90; 3 trials, 2,445 people), and 0.62 (0.47 to 0.82) for neovascular AMD.
- Limitations
- The pooled evidence comes mostly from a single US trial (moderate certainty per Cochrane); in the AREDS2 primary analysis, adding lutein/zeaxanthin was not significant on its own (HR 0.90, 98.7% CI 0.76-1.07), and the benefit is tiny for early AMD. The NIH held a royalty-bearing licence for the AREDS supplement, and the manufacturer supplied pills in the follow-on.
- Sources
- [1] [2] [3] [4]
- Lutein/zeaxanthin is a safer swap for beta carotene Strong evidence
AREDS2 was designed partly to remove beta carotene, which had raised lung cancer risk in smokers in earlier trials. In the 10-year follow-on, beta carotene assignment carried an odds ratio of 1.82 (95% CI 1.06-3.12) for lung cancer — nearly double — versus 1.15 (0.79-1.66, non-significant) for lutein/zeaxanthin, and lutein/zeaxanthin did slightly better than beta carotene on late AMD. Any AREDS product still containing beta carotene should be avoided by current or former smokers.
- Who was studied
- AREDS2 participants secondarily randomised to beta carotene or none; 3,882 followed for 10 years (mean age 72.0, 57.7% women).
- Result
- Lung cancer (self-reported, checked against medical records) and progression to late AMD.
- Effect size
- During the trial there were 23 lung cancers (2.0%) with beta carotene versus 11 (0.9%) without, mostly in former smokers; at 10 years the odds ratio was 1.82 (95% CI 1.06-3.12) for beta carotene and 1.15 (0.79-1.66) for lutein/zeaxanthin, and lutein/zeaxanthin versus beta carotene gave a hazard ratio of 0.85 (0.73-0.98) for late AMD.
- Limitations
- Lung cancer events were few and the direct lutein/zeaxanthin versus beta carotene comparison is exploratory; the lung cancer signal matches older beta carotene trials in smokers, which is why the swap is graded strong.
- Sources
- [1] [2] [3]
- Adding omega-3 fatty acids helps Limited evidence
AREDS2 tested DHA 350 mg plus EPA 650 mg daily and found no effect on AMD progression; at 10 years the hazard ratio was 1.01 (95% CI 0.93-1.09, p=0.91). Products marketing an 'AREDS2 plus omega-3' upgrade are selling an intervention the trial specifically tested and found inert for this endpoint.
- Who was studied
- 4,203 AREDS2 participants aged 50 to 85 at high risk of advanced AMD, randomised to DHA 350 mg plus EPA 650 mg or placebo on top of the AREDS formula.
- Result
- Progression to advanced AMD over a median of 5 years, then to 10 years; omega-3 did not change it.
- Effect size
- No effect: hazard ratio 0.97 (98.7% CI 0.82-1.16) in the trial and 1.01 (95% CI 0.93-1.09, p=0.91) at 10 years.
- Limitations
- Almost everyone also took the AREDS formula, so the trial tested omega-3 as an add-on, not on its own; it says nothing about other omega-3 uses.
- Sources
- [1] [2]
- Prevents AMD or cataracts in healthy eyes Limited evidence
AREDS2 enrolled only people at high risk who already had AMD, so nothing in the trial supports prevention in people with normal retinas. Prevention trials in the general population found that vitamin E, beta carotene and vitamin C do not prevent AMD, and the AREDS2 cataract report found lutein/zeaxanthin did not reduce the rate of cataract surgery overall. Taking it 'for eye health' with no diagnosis is unsupported and, with 80 mg zinc, not risk-free.
- Who was studied
- The 2017 Cochrane prevention review covers 5 trials with 76,756 people from the general population in Australia, Finland and the USA; the AREDS2 cataract report followed 3,159 participants (6,027 eyes) for a median of 4.7 years.
- Result
- New AMD in people without it, and cataract surgery or vision loss; none was reduced.
- Effect size
- Vitamin E: risk ratio 0.97 (95% CI 0.90 to 1.06) for any AMD; beta carotene: 1.00 (0.88 to 1.14); one multivitamin slightly raised it (1.21, 1.02 to 1.43); lutein/zeaxanthin: hazard ratio 0.96 (0.84-1.10) for cataract surgery, with a possible benefit only in the fifth of people eating the least lutein (0.68, 0.48-0.96).
- Limitations
- The prevention trials tested single vitamins or a multivitamin, not the full AREDS2 formula, and no trial has tested lutein/zeaxanthin for AMD prevention; the low-intake cataract result is a subgroup finding. One prevention trial also saw more haemorrhagic strokes with vitamin E (HR 1.74, 1.04 to 2.91).
- Sources
- [5] [6]
- Slows geographic atrophy's advance toward central vision Moderate evidence
In people with geographic atrophy (the dry form of late AMD), a 2025 re-analysis of both trials found that the supplements slowed how fast the atrophy crept toward the centre of the retina, though not how fast it grew overall. This supports continuing the formula after geographic atrophy appears, with modest expectations.
- Who was studied
- Post hoc analysis of 392 eyes (318 people) with geographic atrophy in AREDS and 1,210 eyes (891 people) in AREDS2.
- Result
- Speed of atrophy growth toward the central macula and growth of its area, measured on yearly colour photographs.
- Effect size
- In AREDS, growth toward the centre was 50.7 µm/year with antioxidants versus 72.9 without (p=0.012); in AREDS2 (formula without beta carotene), 80.1 µm/year with lutein/zeaxanthin versus 114.4 without (p=0.011); total area growth did not differ (p=0.63 and p=0.64).
- Limitations
- A post hoc analysis of a secondary, image-based outcome; no effect on overall lesion growth and no visual function result reported, so the real-world benefit is uncertain.
- Sources
- [7]
Dosage & safety
How to take it
Interactions
With medications
- tetracycline and quinolone antibiotics
The 80 mg of zinc chelates the antibiotic in the gut and cuts its absorption substantially. separate the antibiotic from the formula by at least 2 hours
- warfarin, DOACs and antiplatelets
Vitamin E at 400 IU/day has been linked to increased bleeding and haemorrhagic stroke risk. discuss it with your prescriber before starting, and stop before surgery
- penicillamine
Zinc binds penicillamine and reduces its absorption and effect. separate the doses by at least 2 hours
With other supplements
- additional zinc supplements
The formula already supplies 80 mg, double the 40 mg upper limit, so any extra compounds copper depletion and GI upset. drop other zinc sources, or use the 25 mg zinc version of the formula
- additional vitamin E
Stacking pushes vitamin E well past the dose linked to bleeding risk and, in SELECT, to prostate cancer. do not add a separate vitamin E capsule
- iron supplements
Iron and zinc compete for absorption in both directions. take iron at a different time of day
Well-established interactions only — this is not a complete list. Always tell your doctor and pharmacist what you take.
Frequently asked questions
Does the AREDS2 formula work for macular degeneration?
Yes, for a specific group: the evidence is strong that the AREDS2 eye formula slows progression to late AMD by roughly 20-25% over five years in people who already have intermediate AMD or advanced AMD in one eye. It does not cure AMD or improve vision.
Can AREDS2 prevent macular degeneration in healthy eyes?
No. AREDS2 enrolled only people who already had AMD, so nothing supports taking the AREDS2 eye formula for prevention, and a cataract analysis found lutein/zeaxanthin did not reduce cataract surgery overall. With 80 mg of zinc and 400 IU of vitamin E, it is not risk-free without a diagnosis.
What is in the AREDS2 formula?
The AREDS2 eye formula is vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg and copper 2 mg daily. A 25 mg zinc version performed no differently in the trial, and adding omega-3 had no effect on progression.
Can smokers take AREDS eye vitamins?
Current or former smokers should avoid any AREDS product that still contains beta carotene, which nearly doubled lung cancer risk (odds ratio 1.82) in follow-up. The AREDS2 eye formula replaces it with lutein and zeaxanthin.
Scientific references
- Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
- Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration
- A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8
- Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4
- Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
- Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration
Related in Eye health
- Lutein & Zeaxanthin Moderate evidence
- Goji Berry Limited evidence
- Bilberry Limited evidence
- Eyebright Limited evidence
- Meso-Zeaxanthin Moderate evidence
- N-Acetylcarnosine Limited evidence